Icon
+91 94997 68112
Login Register

Descovy - (200mg/ 25mg; Tablet)

Emtricitabine and Tenofovir Alafenamide Fumarate Gilead
200mg/ 25mg; Tablet
More Than $1000 mn
More Than 5
More Than 5
More Than 5
Less Than 5
Less Than 5
 None
DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.
Yes
*** *********** ******* ** *** *** **** ******, *****, ******, ****** ****, *****, ******** *** ***** *** ****. ****** , ****** ****, *****, ******** ,****** ***** * **** ** ** ******* '***, '*** *** **** *********. *****, ***** ***** * **** ** ** ******* '***, '***, '***, '*** *** **** *********. ** ****** **** **** **** ****** ** *** ****. ********* ** *** ****** ** ******, ******** ****** ****** ** ****. ***** ********* ** * **** *** ** ******* '*** *** '*** **** **** **** ***** ** ****** ** *** ****. ***** * *** *** ***** ** *** **** *******.
Descovy Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
****** *** ********* *** ********* ******* ******* ******* *******
***** *** ********* *** ********* ******* ******* ******* *******
****** *** ********* *** ********* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ********* *** *, **** ******* **** ** *** **, ****
***** *** \ ********* *** *, **** ******* **** ** *** **, ****
****** *** \ ********* *** *, **** ******* **** ** *** **, ****
  1. *** *, **** : * ****-** ** ***** *** ***** ** *** * *** *********
  2. *** **, **** : ****** ******** ****** ***** **'* **** ** ****** ** ******* '*** *** '***.
  3. *** *, **** : ***** ******** ****** ***** **'* **** ** ****** ** ******* '***, '***, '***, '***.
  4. *** *, **** : ****** **** *** ***** ******** ****** ***** **'* **** ** ****** ** ******* '*** *** '***.
  5. *** **, **** : ***** ******** ****** ***** **'* **** ** ****** ** ******* '***, '***, '***, '***.
  6. *** **, **** : ******** ******** ****** ***** **'* **** ** ****** ** ******* '*** *** '***.
  7. *** **, **** : ****** ******** ****** ***** **'* **** ** ****** ** ******* '*** *** '***.
  8. *** *, **** : ****** ***** * **** ******* ****** , ****** ****, *****, ******** *** ****** ** ******* '***, '***.
  9. *** *, **** : ****** ***** * **** ******* ***** *** ***** ** ******* '***, '***, '***, '***.
  10. *** **, **** : ***** ******* ** ****** *** **** ** ************* **** ******* ** '*** ******.
  11. *** **, **** : ****** ***** **** ******* ******, *****, ******, ****** ****, *****, ********, *****
  12. *** **, **** : ******** **** ** ** ** ****** '***. ** ** ****** **** ** ** **********.
  13. *** **, **** : ****** ********* *** **** ** ************** ** **** ***.
  14. *** **, **** : ****** ******* ********** **** ***** ***** ************ ********** *** ******* ********* .
  15. *** **, **** : ******** ****** ** ********** ******* ****** ** ****** '***
  16. *** *, **** : ****** ******* ********** **** ******, ***** *** ******** ***** ************ ********** *** ******* *********.
  17. *** **, **** : ****** ******* ********** **** ***** *** ****** ***** ************ ********** *** ******* *********.
  18. *** **, **** : ********* ** ********** ********* ***** ** ******'* *** ******, *** ******** *** ****** ** *** **, ****.
  19. *** **, **** : ********* ******** ********* ******** *** ******* *** *** *** *********. ** ****** ** *** ***** ** **** ***** **** ***.

Descovy - (120mg/ 15mg; Tablet)

Emtricitabine and Tenofovir Alafenamide Fumarate Gilead
120mg/ 15mg; Tablet
More Than $1000 mn
None None
Less Than 5
 None
Less Than 5
 None
DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
Yes
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.